Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 06, 2024 17:05 ET | Source: SAB Biotherapeutics, Inc.

SAB BIO Announces Third Quarter 2024 Financial Results and Provides Company Update

SAB BIO Announces Third Quarter 2024 Financial Results and Provides Company Update
March 24, 2022 06:30 ET | Source: LAVA Therapeutics N.V.

LAVA Therapeutics Provides Business Update and Reports Fourth Quarter and Year End 2021 Financial Results

LAVA-051 shows encouraging initial safety and pharmacodynamic observations; on track for more dose escalation data from Phase 1/2a trial in Q2 2022LAVA-1207 Phase 1/2a trial in mCRPC on track to...
March 10, 2022 06:30 ET | Source: LAVA Therapeutics N.V.

LAVA Therapeutics To Present at the Oppenheimer 32nd Annual Healthcare Conference 2022

UTRECHT, The Netherlands and PHILADELPHIA, March 10, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage biotechnology company focused on developing its proprietary...
February 25, 2022 06:00 ET | Source: SAB Biotherapeutics, Inc.

SAB Biotherapeutics Announces Update to the Phase 3 NIH ACTIV-2 Trial Design Evaluating SAB-185 for Treatment of COVID-19

ACTIV-2 Phase 3 trial continuing as placebo-controlled study in Omicron variant COVID participants SIOUX FALLS, S.D., Feb. 25, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (SAB) (Nasdaq: SABS), a...
January 28, 2022 07:00 ET | Source: LAVA Therapeutics N.V.

Lava Therapeutics Announces Participation in the SVB Leerink 11th Annual Global Healthcare Conference 2022

UTRECHT, The Netherlands and PHILADELPHIA, Jan. 28, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage biotechnology company focused on developing its proprietary...

Next Page keyboard_arrow_right